These five independent cancer cohorts uncovered marked correlation between FGFR1-4 mutations and better immunotherapy outcomes in NSCLC population. Median progression-free survival was 13.2 months (95% CI, 9.1 to 17.3) in the FGFR1-4 mutations group and 3.8 months in the FGFR1-4 wild-type group (95% CI, 3.1 to 4.4) (hazard ratio for disease progression or death, 0.43; 95% CI, 0.30 to 0.62; P=0.0007). Median overall survival was 19.8 months (95% CI, 13.4 to 24.6) in the FGFR1-4 mutations group and 11.0 months (95% CI, 9.1 to 13.0) in the FGFR wild-type group (hazard ratio for death, 0.56; 95% CI, 0.36 to 0.89; P=0.03).